-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Overweight on IRulya Therapeutics, Maintains $70 Price Target

Benzinga·11/19/2026 11:41:09
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates IRulya Therapeutics (NASDAQ:IRLA) with a Overweight and maintains $70 price target.